Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA vs FLORINEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Fludrocortisone is a synthetic corticosteroid with predominantly mineralocorticoid activity, promoting sodium retention and potassium excretion in the distal renal tubules, thereby increasing extracellular fluid volume and blood pressure.
Relief of moderate to moderately severe pain
Partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease,Salt-losing congenital adrenal hyperplasia,Postural hypotension (off-label)
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
0.1 mg orally once daily, with range 0.1-0.2 mg/day. Dose may be divided twice daily if needed.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: 3.5 hours; clinical effect half-life due to mineralocorticoid activity is longer (~12-24 hours), allowing once-daily dosing.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily hepatic via CYP3A4-mediated metabolism; also metabolized by 11β-hydroxysteroid dehydrogenase to inactive metabolites.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Renal: ~80% as metabolites, ~20% unchanged; minimal biliary/fecal elimination.
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
~90% bound to corticosteroid-binding globulin (CBG) and albumin.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Vd: ~0.3 L/kg; distributes mainly into extracellular fluid and binds to renal mineralocorticoid receptors.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
Oral: ~100% (well absorbed); no significant first-pass metabolism.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
No specific dose adjustment recommended based on GFR; use with caution in severe renal impairment due to sodium retention.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
No specific adjustment for Child-Pugh; monitor for fluid overload in severe hepatic impairment.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
0.05-0.1 mg orally once daily; titrate based on response.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Initiate at lower dose (0.05 mg daily) and titrate slowly; monitor for hypertension, hypokalemia, and fluid overload.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
None
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
May cause sodium retention and edema, especially in patients with cardiac disease,Monitor for hypokalemia and hyperglycemia,Increased risk of infections due to immunosuppression,May mask symptoms of infection,Do not use in patients with systemic fungal infections,Avoid abrupt discontinuation after prolonged therapy due to risk of adrenal insufficiency
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Systemic fungal infections,Hypersensitivity to fludrocortisone or any component of the formulation,Concurrent live or attenuated virus vaccines (relative)
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Avoid excessive licorice (glycyrrhizin) which can enhance mineralocorticoid effects and worsen hypokalemia. Maintain a low-sodium diet to reduce fluid retention and hypertension. Increase potassium-rich foods if not contraindicated.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Fludrocortisone (Florinef) is a corticosteroid with mineralocorticoid activity. In animal studies, corticosteroids have been associated with cleft palate and other malformations. Human data are limited. First trimester exposure may slightly increase risk of oral clefts. Second and third trimester use may suppress fetal adrenal function, leading to neonatal adrenal insufficiency. Overall risk is low with short-term use, but chronic high doses should be avoided.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Fludrocortisone is excreted into breast milk in small amounts. The milk-to-plasma ratio is unknown. At typical doses, the amount ingested by the infant is likely to be low and not expected to cause adverse effects. However, monitor infant for signs of adrenal suppression. Use with caution, especially with high maternal doses.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Pharmacokinetic changes in pregnancy (increased volume of distribution, increased renal clearance) may reduce fludrocortisone levels, potentially requiring dose adjustment to maintain desired effect. Dose should be titrated based on clinical response (e.g., blood pressure, electrolyte levels). No specific dosing guidelines; individualize therapy.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Monitor for signs of edema, hypertension, and hypokalemia. Use lowest effective dose. Caution in patients with heart failure, hypertension, or renal impairment. Do not abruptly discontinue; taper slowly. May interfere with cortisol assays.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
Take exactly as prescribed; do not stop suddenly without doctor's advice.,Weigh yourself daily and report rapid weight gain or swelling.,Monitor blood pressure regularly.,Eat a low-salt diet to help control fluid retention.,Report signs of high potassium (muscle weakness, irregular heartbeat) or low potassium (cramps, fatigue).,Carry medical ID indicating you take fludrocortisone.,Avoid excessive licorice intake (can worsen potassium loss).,May cause increased thirst and urination.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA vs FLORINEF, answered by our medical review team.
ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. FLORINEF is a Corticosteroid (Mineralocorticoid) that works by Fludrocortisone is a synthetic corticosteroid with predominantly mineralocorticoid activity, promoting sodium retention and potassium excretion in the distal renal tubules, thereby increasing extracellular fluid volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA and FLORINEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. The standard adult dose of FLORINEF is: 0.1 mg orally once daily, with range 0.1-0.2 mg/day. Dose may be divided twice daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA and FLORINEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . FLORINEF is classified as Category C. Fludrocortisone (Florinef) is a corticosteroid with mineralocorticoid activity. In animal studies, corticosteroids have been associated with cleft palate and other malformations. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.